Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses. 2009

Yi Liu, and John McNevin, and Morgane Rolland, and Hong Zhao, and Wenjie Deng, and Janine Maenza, and Claire E Stevens, and Ann C Collier, and M Juliana McElrath, and James I Mullins
Department of Microbiology, University of Washington School of Medicine, Seattle, Washington 98195-8070, USA. yiliu197@u.washington.edu

BACKGROUND The epitope specificities and antiviral activities of class I HLA-restricted CD8(+) T cells, especially those induced during human immunodeficiency virus type 1 (HIV-1) primary infection, are important considerations in designing HIV-1 vaccines. Conserved epitopes may be more commonly and persistently recognized than variable epitopes, as they may be more likely to be present in infecting viruses. However, some studies have shown preferential or similar targeting of variable versus conserved epitopes during primary infection. METHODS We analyzed cytotoxic T-lymphocyte (CTL) responses toward predefined conserved and variable epitopes in 45 subjects during primary (n = 34) and/or chronic infection (n = 16). RESULTS Conserved and variable CTL epitopes were recognized with similar probabilities, whereas conserved epitopes generally elicited subdominant responses during both primary and chronic infection. During primary infection, CTL responses against Gag versus responses against Env and variable epitopes tended to be associated with lower and higher viral loads, respectively. During chronic infection, Env-specific responses tended to be associated with lower CD4(+) cell counts. CONCLUSIONS Subdominant CTL recognition of conserved HIV-1 epitopes commonly occurs from the primary through chronic stages of HIV-1 infection. These findings underscore the challenge in designing T cell-based vaccines that can induce immunodominant CTL responses to conserved HIV-1 regions.

UI MeSH Term Description Entries
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018414 CD8-Positive T-Lymphocytes A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes. Suppressor T-Lymphocytes, CD8-Positive,T8 Cells,T8 Lymphocytes,CD8-Positive Lymphocytes,Suppressor T-Cells, CD8-Positive,CD8 Positive Lymphocytes,CD8 Positive T Lymphocytes,CD8-Positive Lymphocyte,CD8-Positive Suppressor T-Cell,CD8-Positive Suppressor T-Cells,CD8-Positive Suppressor T-Lymphocyte,CD8-Positive Suppressor T-Lymphocytes,CD8-Positive T-Lymphocyte,Cell, T8,Cells, T8,Lymphocyte, CD8-Positive,Lymphocyte, T8,Lymphocytes, CD8-Positive,Lymphocytes, T8,Suppressor T Cells, CD8 Positive,Suppressor T Lymphocytes, CD8 Positive,Suppressor T-Cell, CD8-Positive,Suppressor T-Lymphocyte, CD8-Positive,T-Cell, CD8-Positive Suppressor,T-Cells, CD8-Positive Suppressor,T-Lymphocyte, CD8-Positive,T-Lymphocyte, CD8-Positive Suppressor,T-Lymphocytes, CD8-Positive,T-Lymphocytes, CD8-Positive Suppressor,T8 Cell,T8 Lymphocyte
D018984 Epitopes, T-Lymphocyte Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen. T-Cell Epitopes,T-Lymphocyte Epitopes,T-Cell Epitope,T-Lymphocyte Epitope,Epitope, T-Cell,Epitope, T-Lymphocyte,Epitopes, T Lymphocyte,Epitopes, T-Cell,T Cell Epitope,T Cell Epitopes,T Lymphocyte Epitope,T Lymphocyte Epitopes

Related Publications

Yi Liu, and John McNevin, and Morgane Rolland, and Hong Zhao, and Wenjie Deng, and Janine Maenza, and Claire E Stevens, and Ann C Collier, and M Juliana McElrath, and James I Mullins
July 2009, AIDS (London, England),
Yi Liu, and John McNevin, and Morgane Rolland, and Hong Zhao, and Wenjie Deng, and Janine Maenza, and Claire E Stevens, and Ann C Collier, and M Juliana McElrath, and James I Mullins
November 2003, Journal of immunology (Baltimore, Md. : 1950),
Yi Liu, and John McNevin, and Morgane Rolland, and Hong Zhao, and Wenjie Deng, and Janine Maenza, and Claire E Stevens, and Ann C Collier, and M Juliana McElrath, and James I Mullins
January 2018, Human vaccines & immunotherapeutics,
Yi Liu, and John McNevin, and Morgane Rolland, and Hong Zhao, and Wenjie Deng, and Janine Maenza, and Claire E Stevens, and Ann C Collier, and M Juliana McElrath, and James I Mullins
January 1993, Journal of medical primatology,
Yi Liu, and John McNevin, and Morgane Rolland, and Hong Zhao, and Wenjie Deng, and Janine Maenza, and Claire E Stevens, and Ann C Collier, and M Juliana McElrath, and James I Mullins
August 2017, AIDS research and human retroviruses,
Yi Liu, and John McNevin, and Morgane Rolland, and Hong Zhao, and Wenjie Deng, and Janine Maenza, and Claire E Stevens, and Ann C Collier, and M Juliana McElrath, and James I Mullins
July 2010, European journal of immunology,
Yi Liu, and John McNevin, and Morgane Rolland, and Hong Zhao, and Wenjie Deng, and Janine Maenza, and Claire E Stevens, and Ann C Collier, and M Juliana McElrath, and James I Mullins
November 1998, The Journal of clinical investigation,
Yi Liu, and John McNevin, and Morgane Rolland, and Hong Zhao, and Wenjie Deng, and Janine Maenza, and Claire E Stevens, and Ann C Collier, and M Juliana McElrath, and James I Mullins
January 2000, AIDS research and human retroviruses,
Yi Liu, and John McNevin, and Morgane Rolland, and Hong Zhao, and Wenjie Deng, and Janine Maenza, and Claire E Stevens, and Ann C Collier, and M Juliana McElrath, and James I Mullins
December 1996, AIDS research and human retroviruses,
Yi Liu, and John McNevin, and Morgane Rolland, and Hong Zhao, and Wenjie Deng, and Janine Maenza, and Claire E Stevens, and Ann C Collier, and M Juliana McElrath, and James I Mullins
May 2001, Infection and immunity,
Copied contents to your clipboard!